Skip to main content

Table 2 Comparison of OCS participants to non-participants from four recruiting sites

From: Representativeness of an HIV cohort of the sites from which it is recruiting: results from the Ontario HIV Treatment Network (OHTN) cohort study

Characteristics‡ Consented Declined Not approached  
  (n =1861) (n =216) (n =502) p value
Site     
  Windsor 128 (7%) <6 (<3%) 94 (19%) <.0001
  UHN 525 (28%) 162 (75%) 226 (45%)  
  Ottawa 293 (16%) 35 (16%) 123 (25%)  
  MLMC 915 (49%) <16 (<7%) 59 (12%)  
Age 46 (40–52) 45 (37–51) 44 (39–50) 0.008
Male 1632 (88%) 154 (71%) 374 (75%) <.0001
Risk Factor     
  MSM 1429 (77%) 90 (42%) 229 (47%) <.0001
  IDU 180 (10%) 13 (6%) 49 (10%) 0.19
  Heterosexual 325 (18%) 93 (43%) 177 (36%) <.0001
  Blood product 100 (5%) 10 (5%) 30 (7%) 0.46
Race     
  Caucasian 1329 (72%) 76 (41%) 240 (57%) <.0001
  Black/African 259 (14%) 75 (40%) 129 (31%)  
  Other 259 (10%) 35 (19%) 49 (11%)  
Born in Canada 1264 (69%) 78 (39%) 224 (52%) <.0001
Years since HIV+ test 12 (5–18) 7 (5–14) 8 (4–13) <.0001
On cART 1487 (80%) 156 (73%) 362 (73%) 0.001
CD4 count (cells/mm3) 480 (340–650) 450 (296–615) 420 (281–587) <.0001
  <200 155 (8%) 31 (14%) 70 (15%) <.0001
  200-500 851 (46%) 102 (47%) 227 (47%)  
  >500 853 (46%) 82 (38%) 185 (38%)  
VL <50 copies/mL 1379 (74%) 160 (75%) 297 (62%) <.0001
  1. ‡ median (interquartile range) or frequency (percent).
  2. OCS Ontario HIV Treatment Network Cohort Study, UHN University Health Network, MLMC Maple Leaf Medical Clinic, MSM men who have sex with men, IDU injection drug use, cART combination antiretroviral therapy, VL viral load.